CDK8 and breast carcinoma: Furthermore, CDK8/19i potentiated growth inhibitory effects of the estrogen antagonist fulvestrant in breast cancer cells [43], reversed castration resistance of advanced prostate cancers [44], stimulated tumor surveillance by NK cells [45] and enhanced the antitumor effects of CAR-T cells [46].